Cargando…
Correction: Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513965/ https://www.ncbi.nlm.nih.gov/pubmed/36162983 http://dx.doi.org/10.1186/s12882-022-02950-0 |
| _version_ | 1784798176437338112 |
|---|---|
| author | Wang, Bihua Zhu, Zhidan Huang, Feng Huang, Haowen Tu, Luxia Wang, Ying Zheng, Linfeng Zhou, Jing Wei, Xin |
| author_facet | Wang, Bihua Zhu, Zhidan Huang, Feng Huang, Haowen Tu, Luxia Wang, Ying Zheng, Linfeng Zhou, Jing Wei, Xin |
| author_sort | Wang, Bihua |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9513965 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-95139652022-09-28 Correction: Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients Wang, Bihua Zhu, Zhidan Huang, Feng Huang, Haowen Tu, Luxia Wang, Ying Zheng, Linfeng Zhou, Jing Wei, Xin BMC Nephrol Correction BioMed Central 2022-09-26 /pmc/articles/PMC9513965/ /pubmed/36162983 http://dx.doi.org/10.1186/s12882-022-02950-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Wang, Bihua Zhu, Zhidan Huang, Feng Huang, Haowen Tu, Luxia Wang, Ying Zheng, Linfeng Zhou, Jing Wei, Xin Correction: Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients |
| title | Correction: Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients |
| title_full | Correction: Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients |
| title_fullStr | Correction: Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients |
| title_full_unstemmed | Correction: Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients |
| title_short | Correction: Anti-phospholipase A2 receptor antibody levels at diagnosis predicts outcome of TAC-based treatment for idiopathic membranous nephropathy patients |
| title_sort | correction: anti-phospholipase a2 receptor antibody levels at diagnosis predicts outcome of tac-based treatment for idiopathic membranous nephropathy patients |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9513965/ https://www.ncbi.nlm.nih.gov/pubmed/36162983 http://dx.doi.org/10.1186/s12882-022-02950-0 |
| work_keys_str_mv | AT wangbihua correctionantiphospholipasea2receptorantibodylevelsatdiagnosispredictsoutcomeoftacbasedtreatmentforidiopathicmembranousnephropathypatients AT zhuzhidan correctionantiphospholipasea2receptorantibodylevelsatdiagnosispredictsoutcomeoftacbasedtreatmentforidiopathicmembranousnephropathypatients AT huangfeng correctionantiphospholipasea2receptorantibodylevelsatdiagnosispredictsoutcomeoftacbasedtreatmentforidiopathicmembranousnephropathypatients AT huanghaowen correctionantiphospholipasea2receptorantibodylevelsatdiagnosispredictsoutcomeoftacbasedtreatmentforidiopathicmembranousnephropathypatients AT tuluxia correctionantiphospholipasea2receptorantibodylevelsatdiagnosispredictsoutcomeoftacbasedtreatmentforidiopathicmembranousnephropathypatients AT wangying correctionantiphospholipasea2receptorantibodylevelsatdiagnosispredictsoutcomeoftacbasedtreatmentforidiopathicmembranousnephropathypatients AT zhenglinfeng correctionantiphospholipasea2receptorantibodylevelsatdiagnosispredictsoutcomeoftacbasedtreatmentforidiopathicmembranousnephropathypatients AT zhoujing correctionantiphospholipasea2receptorantibodylevelsatdiagnosispredictsoutcomeoftacbasedtreatmentforidiopathicmembranousnephropathypatients AT weixin correctionantiphospholipasea2receptorantibodylevelsatdiagnosispredictsoutcomeoftacbasedtreatmentforidiopathicmembranousnephropathypatients |